Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 21, 2013; 19(47): 8850-8860
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8850
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8850
Cellular reprogramming and hepatocellular carcinoma development
Yun-Wen Zheng, Yun-Zhong Nie, Hideki Taniguchi, Department of Regenerative Medicine, Graduate School of Medicine, Yokohama City University, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
Yun-Wen Zheng, Jiangsu University Hospital, Zhenjiang, Jiangsu 212001, China
Hideki Taniguchi, Advanced Medical Research Center, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan
Author contributions: Zheng YW and Nie YZ contributed equally to this work; Zheng YW designed, wrote, reviewed and revised the manuscript; Nie YZ wrote the paper; Taniguchi H approved the final version.
Supported by Grants-in-Aid No.18591421, No. 20591531 and No. 23591872 for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grant from the Research Center Network for Realization of Regenerative Medicine and grants for Strategic Promotion of Innovative Research and Development (S-innovation, 62890004) from the Japan Science and Technology Agency
Correspondence to: Hideki Taniguchi, MD, PhD, Department of Regenerative Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan. rtanigu@med.yokohama-cu.ac.jp
Telephone: +81-45-7878963 Fax: +81-45-7878963
Received: September 28, 2013
Revised: November 13, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Revised: November 13, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Core Tip
Core tip: Cellular reprogramming contributes to chemoresistance and radioresistance and cancer recurrence in hepatocellular carcinoma (HCC). Recent findings on cellular reprogramming in HCC are summarized and discussed, including stemness transcription factors, DNA methylation, miRNAs, tumor microenvironments, and signaling pathways. The novel therapeutic concept of reprogramming control therapy is also described, which may be a promising strategy for HCC therapy in the future.